Drugs / Donor FMT
Donor FMT
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05791396 | Feb 2024 → Apr 2026 overdue | bacterial infectious disease | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04759001 | Feb 2021 → Mar 2026 overdue | bacterial infectious disease | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03691987 | Feb 2019 → Mar 2023 | myalgic encephalomeyelitis/chronic fatigue syndrome | University Hospital of North Norway | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor FMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03691987 ↗ |
| Known as | D-FMT | “Donor FMT (D-FMT)” NCT05791396 ↗ |
| Known as | donor fecal microbiota transplant | “Participants will be randomized to treatment by preprocessed thawed donor fecal microbiota transplant or preprocessed thawed autologous fecal microbiota transplant.” NCT03691987 ↗ |
| Known as | Preprocessed thawed donor FMT | “Biological: Preprocessed thawed donor FMT” NCT03691987 ↗ |
| Action | Restore | “The restoration of healthy gut microbiota by fecal microbiota transplantation (FMT) may lead to the eradication of antibiotic-resistant bacteria.” NCT05791396 ↗ |
| Modality | Other / unclassified | “administration, in the recipients' gut, of donor microbiota through FMT” NCT05791396 ↗ |
| Route | Other | “Delivered as an enema using the same equipment and technique as X-ray of the colon” NCT03691987 ↗ |